Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milad Moradi

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Virology Journal|July 18, 2023
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trialMasoud Solaymani-Dodaran, Pouria Basiri, Milad Moradi, et al.
Vaccine: X|November 9, 2023
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trialAkram Ansarifar, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, et al.
BMC Infectious Diseases|February 24, 2023
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 yearsFatemeh Gholami, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 13, 2024
Canadian Spine Society: 24th Annual Scientific Conference, Wednesday, February 28 - Saturday, March 2, Fairmont Chateau Whistler, Whistler, B.C., CanadaAntoine Dionne, Majeed Al-Zakri, Hubert Labelle, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Virology Journal|July 18, 2023
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trialMasoud Solaymani-Dodaran, Pouria Basiri, Milad Moradi, et al.
Vaccine: X|November 9, 2023
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trialAkram Ansarifar, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, et al.
BMC Infectious Diseases|February 24, 2023
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 yearsFatemeh Gholami, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 13, 2024
Canadian Spine Society: 24th Annual Scientific Conference, Wednesday, February 28 - Saturday, March 2, Fairmont Chateau Whistler, Whistler, B.C., CanadaAntoine Dionne, Majeed Al-Zakri, Hubert Labelle, et al.
Pageof 3